Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2

被引:61
|
作者
Otyepka, M
Krystof, V
Havlícek, L
Siglerová, V
Strnad, M
Koca, J
机构
[1] Masaryk Univ, Fac Sci, Lab Biomol Struct & Dynam, CS-61137 Brno, Czech Republic
[2] Palacky Univ, Fac Sci, Dept Inorgan & Phys Chem, Olomouc 77146, Czech Republic
[3] Palacky Univ, Fac Sci, Lab Growth Regulators, Olomouc 78371, Czech Republic
[4] Inst Expt Bot, Olomouc 78371, Czech Republic
[5] Charles Univ Prague, Fac Med 1, Cent Radioisotope Lab, Prague 12108 2, Czech Republic
[6] Inst Expt Bot, Isotope Lab, Prague 14220 4, Czech Republic
关键词
D O I
10.1021/jm990506w
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The cell division cycle is controlled by cyclin-dependent kinases (cdk), which consist of a catalytic subunit (cdk1-cdk8) and a regulatory subunit (cyclin A-H). Purine-like inhibitors of cyclin-dependent kinases have recently been found to be of potential use as anticancer drugs. Rigid and flexible docking techniques were used for analysis of binding mode and design of new inhibitors. X-ray structures of three (ATP, olomoucine, roscovitine) cdk2 complexes were available at the beginning of the study and were used to optimize the docking parameters. The new potential inhibitors were then docked into the cdk2 enzyme, and the enzyme/inhibitor interaction energies were calculated and tested against the assayed activities of cdk1 (37 compounds) and cdk2 (9 compounds). A significant rank correlation between the activity and the rigid docking interaction energy has been found. This implies that (i) the rigid docking can be used as a tool for qualitative prediction of activity and (ii) values obtained by the rigid docking technique into the cdk2 active site can also be used for the prediction of cdk1 activity. While the resulting geometries obtained by the rigid docking are in good agreement with the X-ray data, the flexible docking did not always produce the same inhibitor conformation as that found in the crystal.
引用
收藏
页码:2506 / 2513
页数:8
相关论文
共 50 条
  • [31] Identification of Potential Phytochemicals Against Cyclin-Dependent Kinase 1 and Cyclin-Dependent Kinase 2: A Molecular Docking and Molecular Dynamic Approach
    Pawar, Swaranjali
    Shinde, Shalini
    Chavan, Pooja
    Rathod, S.
    Choudhari, P.
    Arvindekar, Snehal
    Patil, S.
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 86 (01) : 322 - 329
  • [32] Cyclin-dependent kinase inhibitors for treating cancer
    Toogood, PL
    MEDICINAL RESEARCH REVIEWS, 2001, 21 (06) : 487 - 498
  • [33] Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
    Tadesse, Solomon
    Caldon, Elizabeth C.
    Tilley, Wayne
    Wang, Shudong
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (09) : 4233 - 4251
  • [34] Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs
    Krystof, Vladimir
    Uldrijan, Stjepan
    CURRENT DRUG TARGETS, 2010, 11 (03) : 291 - 302
  • [35] Structural Basis for Interaction of Inhibitors with Cyclin-Dependent Kinase 2
    Canduri, Fernanda
    de Azevedo, Walter Filgueira, Jr.
    CURRENT COMPUTER-AIDED DRUG DESIGN, 2005, 1 (01) : 53 - 64
  • [36] Cyclins, Cyclin-Dependent Kinases, and Cyclin-Dependent Kinase Inhibitors in the Mouse Nervous System
    Alice Grison
    Suzana Atanasoski
    Molecular Neurobiology, 2020, 57 : 3206 - 3218
  • [37] Cyclins, Cyclin-Dependent Kinases, and Cyclin-Dependent Kinase Inhibitors in the Mouse Nervous System
    Grison, Alice
    Atanasoski, Suzana
    MOLECULAR NEUROBIOLOGY, 2020, 57 (07) : 3206 - 3218
  • [38] Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment
    Mou, Jiajia
    Chen, Danghui
    Deng, Yanru
    MEDICINAL CHEMISTRY, 2020, 16 (03) : 307 - 325
  • [39] Ras versus cyclin-dependent kinase inhibitors
    Lloyd, AC
    CURRENT OPINION IN GENETICS & DEVELOPMENT, 1998, 8 (01) : 43 - 48
  • [40] Selectivity and potency of cyclin-dependent kinase inhibitors
    Jayalakshmi Sridhar
    Nagaraju Akula
    Nagarajan Pattabiraman
    The AAPS Journal, 8